Literature DB >> 25633781

2014 FDA drug approvals.

Asher Mullard.   

Abstract

Mesh：

Year:  2015        PMID： 25633781     DOI： 10.1038/nrd4545

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  New checkpoint inhibitors ride the immunotherapy tsunami.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

2.  All-oral HCV therapies near approval.

Authors:  Man Tsuey Tse
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

3.  Breakthrough programme turns two.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694

4.  2013 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

5.  Momentum builds around new antibiotic business models.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2014-10       Impact factor: 84.694
  5 in total
  26 in total

Review 1.  Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development.

Authors:  Dheeraj S Tomar; Sandeep Kumar; Satish K Singh; Sumit Goswami; Li Li
Journal:  MAbs       Date:  2016-01-06       Impact factor: 5.857

2.  2015 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2016-02       Impact factor: 84.694

Review 3.  High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.

Authors:  Genevieve Conant; Benjamin Fook Lun Lai; Rick Xing Ze Lu; Anastasia Korolj; Erika Yan Wang; Milica Radisic
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

Review 4.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 5.  Drug combination therapy increases successful drug repositioning.

Authors:  Wei Sun; Philip E Sanderson; Wei Zheng
Journal:  Drug Discov Today       Date:  2016-05-27       Impact factor: 7.851

Review 6.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

7.  Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.

Authors:  Hongyan He; Xiyan Nan; Shuang Liu; Liangren Zhang; Zhenjun Yang; Yun Wu; Lihe Zhang
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

8.  A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.

Authors:  Andrew M Stern; Mark E Schurdak; Ivet Bahar; Jeremy M Berg; D Lansing Taylor
Journal:  J Biomol Screen       Date:  2016-03-08

Review 9.  Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction.

Authors:  Wei Chen; Bryant C Yung; Zhiyong Qian; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

10.  Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvals.

Authors:  Emily M Lord; Isabelle R Weir; Ludovic Trinquart
Journal:  J Clin Epidemiol       Date:  2018-07-02       Impact factor: 6.437
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.